SABCS 2025
SABCS 2025: High-Level Review of Select Data
The 2025 San Antonio Breast Cancer Symposium (SABCS 2025) featured some exciting presentations. The early breast cancer highlights at SABCS 2025 included the landmark lidERA trial, which explored the ...
SABCS 2025: Top Picks From a Breast Cancer Specialist
Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior D...
Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence
Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai, discusses the performance of experimental multimodal artificial intelligence (AI) models integrating clinical, molecular, and his...
Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated pa...
Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data
Jame Abraham, MD, FACP, discusses follow-up data from the DESTINY Breast-05 and DESTINY Breast-11 trials of fam-trastuzumab deruxtecan-nki (T-DXd) for HER2-positive early breast cancer. DESTINY Breast...
Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estr...
AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments
Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification among pati...
Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?
Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospec...
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
A mobile health tool designed specifically for adolescent and young adult (AYA) breast cancer survivors significantly improved overall quality of life and reduced symptoms related to vaginal and arm p...
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's ris...
Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors
New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alon...
Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer
Similar recurrence and regional recurrence-free survival rates were observed at 5 years with or without a sentinel lymph node biopsy in patients with clinically node-negative cT1-2 breast cancer treat...
Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy–Refractory Advanced Breast Cancers
Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemo...
Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the curren...
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and su...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...
P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti–PD-1 Therapy in Early Breast Cancer
Preoperative radiation therapy added to anti–PD-1 immune checkpoint inhibition led to a significant increase in T-cell infiltration in patients with hormone receptor–positive/HER2-negative early-stage...
